Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Oct;26(4):446–449. doi: 10.1128/aac.26.4.446

Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys.

H Kim, D Loebenberg, A Marco, S Symchowicz, C Lin
PMCID: PMC179942  PMID: 6517539

Abstract

The pharmacokinetics of Sch 28191, the N-D-ornithyl methyl ester of amphotericin B, and amphotericin B were studied in mice, rats, dogs, and cynomolgus monkeys after an intravenous dose of 0.6 mg/kg was administered. The decline in the concentrations of Sch 28191 and amphotericin B in serum appeared to be biphasic in nature. The half-life at the distribution phase and the half-life at the elimination phase of Sch 28191 were similar to those of amphotericin B in all animals studied. The half-life at the distribution phase in serum was 0.9 to 1.5 h in all animals studied. The half-lives at the elimination phase in serum were 25 to 28 h in mice, 16 to 18 h in rats, 44 to 47 h in dogs, and 35 h in cynomolgus monkeys. The areas under the serum concentration-time curves of Sch 28191 were five- to eightfold larger than those of amphotericin B in rats, dogs, and cynomolgus monkeys but were only slightly larger than those of amphotericin B in mice. In dogs, the urinary excretion (over 9 days) of unchanged drug accounted for 23% of the Sch 28191 dose and 25% of the amphotericin B dose. The concentrations of Sch 28191 in serum were also studied after the intravenous administration of 0.3, 0.6, or 1.25 mg/kg to dogs. The serum concentration-time curves were parallel for these doses. There was a linear relationship between the areas under the concentration-time curves and the doses, indicating dose proportionality.

Full text

PDF
446

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bindschadler D. D., Bennett J. E. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis. 1969 Oct;120(4):427–436. doi: 10.1093/infdis/120.4.427. [DOI] [PubMed] [Google Scholar]
  2. Craven P. C., Ludden T. M., Drutz D. J., Rogers W., Haegele K. A., Skrdlant H. B. Excretion pathways of amphotericin B. J Infect Dis. 1979 Sep;140(3):329–341. doi: 10.1093/infdis/140.3.329. [DOI] [PubMed] [Google Scholar]
  3. Jagdis F. A., Hoeprich P. D., Lawrence R. M., Schaffner C. P. Comparative pharmacology of amphotericin B and amphotericin B methyl ester in the non-human primate, Macacca mulatta. Antimicrob Agents Chemother. 1977 Nov;12(5):582–590. doi: 10.1128/aac.12.5.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Kim H., Lin C. High-pressure liquid chromatographic method for determination of Sch 28191 in biological fluids. Antimicrob Agents Chemother. 1984 Jan;25(1):45–48. doi: 10.1128/aac.25.1.45. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES